This is the seventh year in a row the program increased savings.
The Medicare Shared Savings Program collectively saved Medicare $4.1 billion last year and $1.9 billion after accounting for shared savings payments.
It is the highest annual savings to date for the accountable care organization model that served 10.6 million seniors in 2020.
The accountable care organizations had an average quality score of 97.8% and 60 earned a score of 100%. The results are an improvement over the $2.6 billion and $1.2 billion in gross and net savings in 2019.
“Today’s data underscore the need for policymakers to do all they can to grow the ACO model and extend the program’s benefits to more patients,” Clif Gaus, Sc.D., president and chief executive officer of the National Association of ACOs, said in a statement. “We currently have the fewest number of Shared Savings Program ACOs since 2017. That trend must be reversed, given continued debate about ways to improve our health system.”
Additionally, in 2020 there was $390 in gross savings per beneficiary. And 67% of ACOs earned shared savings. In shared saving payments, ACOs made $2.3 billion. Three-quarters of shared savings-only ACOs produced gross savings and 55% earned shared savings. What’s more, 97% of at-risk ACOs produced gross savings and 88% earned shared savings.
More data demonstrate ACOs are lowering Medicare spending by 1-2%, which can be tens of billions of dollars of reduced Medicare spending annually.
ACOs played a key role in managing patient care at the onset of the COVID-19 pandemic and throughout 2020. The organizations were proactive in outreach to high-risk patients to keep them healthy, and established telehealth and remote monitoring and effectively managed home visits and post-acute care to reduce transmission of the virus.
The purpose of ACOs is to provide another method besides fee-for-service by holding groups of physicians, hospitals, and other providers accountable for the cost and quality of a particular group of patients. ACOs can share with Medicare savings earned if they meet a spending and quality metrics.
Positive Results for Ruxolitinib Cream in Children with Atopic Dermatitis Presented in Ongoing Study
March 18th 2024Ruxolitinib cream showed positive results in children 2- to 11-years-old with mild to moderate atopic dermatitis (AD), according to data of a poster presented at the American Academy of Dermatology Annual Meeting in San Diego from March 8 to 12.
Read More
FDA Updates for Week of March 11: First CAR-T for CLL/SLL and First NASH Treatment
March 16th 2024The FDA this week approved a few firsts: the first treatment for NASH and the first CAR-T cell therapy for CLL/SLL. Other approvals include Tevimbra for esophageal cancer; Livmarli for second liver disease indication; and Praluent for children with genetic form of high cholesterol. The FDA also issued a CRL for monthly MS drug. Additionally, Celltrion submitted an application for an interchangeable Xolair biosimilar.
Read More
A Deep Dive into Predictive and Generative AI with Lynn Carroll of HSBlox
January 3rd 2024In this month’s episode, Briana Contreras, an editor of MHE, chatted with Lynn Carroll, executive of HSBlox, about the difference between predictive and generative AI, yet how each works together in preventive healthcare.
Listen
Transforming the management of genetic testing
March 15th 2024This e-book will explain where the current genetic test management system is inadequate and how a new approach designed specifically for genetic testing will perform better and provide more meaningful and actionable results.
Read More